Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 561 to 570 of 2194 total matches.

Elvitegravir (Vitekta) for HIV

   
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016  (Issue 1486)
inhibitor (PI) plus ritonavir and other antiretroviral drugs for treatment of HIV-1 infection in treatment ...
The FDA has approved elvitegravir (Vitekta – Gilead), an integrase strand transfer inhibitor (INSTI), for use with a protease inhibitor (PI) plus ritonavir and other antiretroviral drugs for treatment of HIV-1 infection in treatment-experienced adults. Elvitegravir is also available in a fixed-dose combination (Stribild) with the pharmacokinetic enhancer cobicistat and the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir disoproxil fumarate (DF). A similar combination (Genvoya) that includes tenofovir alafenamide instead of tenofovir DF was recently...
Med Lett Drugs Ther. 2016 Jan 18;58(1486):10-1 | Show Introduction Hide Introduction

Mepolizumab (Nucala) for Severe Eosinophilic Asthma

   
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016  (Issue 1486)
severe disease with high eosinophil levels in blood and sputum despite treatment with a glucocorticoid.1 ...
The FDA has approved mepolizumab (Nucala - GSK), a subcutaneously injected humanized interleukin-5 (IL-5) antagonist monoclonal antibody, for maintenance treatment of severe asthma in patients ≥12 years old who have an eosinophilic phenotype.
Med Lett Drugs Ther. 2016 Jan 18;58(1486):11-2 | Show Introduction Hide Introduction

Naloxone (Narcan) Nasal Spray for Opioid Overdose

   
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016  (Issue 1485)
, but naloxone solution has been administered intranasally off-label, using a mucosal atomizer device.1 The drug ...
The recent increase in deaths due to overdose of heroin and prescription opioids in the US has renewed interest in the opioid antagonist naloxone, particularly in making it available to first responders and to relatives and close friends of persons using heroin or taking prescription opioids. IV or IM administration by healthcare professionals is preferred, but peripheral venous access may be difficult to obtain in IV drug abusers, and exposure to their blood may be hazardous.
Med Lett Drugs Ther. 2016 Jan 4;58(1485):1-2 | Show Introduction Hide Introduction

Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension

   
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016  (Issue 1485)
phosphodiesterase-5 (PDE5) inhibitors, endothelin receptor antagonists, and a guanylate cyclase stimulator.1 ...
The FDA has approved the use of ambrisentan (Letairis) and tadalafil (Adcirca) together for treatment of pulmonary arterial hypertension (PAH). It is the first 2-drug regimen to be approved for this indication.
Med Lett Drugs Ther. 2016 Jan 4;58(1485):2-4 | Show Introduction Hide Introduction

Eluxadoline (Viberzi) for Irritable Bowel Syndrome with Diarrhea

   
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016  (Issue 1485)
limited by serious GI adverse effects such as ischemic colitis.1 MECHANISM OF ACTION — Eluxadoline ...
The FDA has approved eluxadoline (Viberzi – Actavis), a mu-opioid receptor agonist and delta-opioid receptor antagonist, for oral treatment of adults with irritable bowel syndrome with diarrhea (IBS-D).
Med Lett Drugs Ther. 2016 Jan 4;58(1485):4-5 | Show Introduction Hide Introduction

ColciGel - A Homeopathic Colchicine Gel for Gout

   
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016  (Issue 1485)
consist of very large dilutions of "proven" substances. Serial dilutions of 1:10 are designated ...
Homeopathic drugs characteristically consist of very large dilutions of "proven" substances. Serial dilutions of 1:10 are designated by the Roman numeral X. ColciGel (Gensco), a prescription homeopathic gel containing a 10,000-fold dilution of colchicine (colchicinum 4X), is now being marketed for topical treatment and prophylaxis of gout.
Med Lett Drugs Ther. 2016 Jan 4;58(1485):5-6 | Show Introduction Hide Introduction

In Brief: New Indications for Harvoni

   
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016  (Issue 1485)
approved by the FDA in 2014 for treatment of hepatitis C virus (HCV) genotype 1 infection,1 has now been ...
Harvoni, a once-daily fixed-dose combination of the direct-acting antiviral agents ledipasvir and sofosbuvir approved by the FDA in 2014 for treatment of hepatitis C virus (HCV) genotype 1 infection,1 has now been approved for use in patients infected with HCV genotype 4, 5, or 6, and in patients co-infected with HCV and HIV-1. A 12-week course of treatment with Harvoni plus ribavirin has also been approved as an alternative to 24 weeks of Harvoni alone for treatment-experienced, cirrhotic patients with HCV genotype 1 infection.HCV genotypes 4, 5, and 6 are responsible for <2% of HCV cases...
Med Lett Drugs Ther. 2016 Jan 4;58(1485):6 | Show Introduction Hide Introduction

Intravenous Diclofenac (Dyloject)

   
The Medical Letter on Drugs and Therapeutics • Dec 21, 2015  (Issue 1484)
shown to reduce opioid use and the incidence of opioid-related adverse effects.1 Administration ...
The FDA has approved Dyloject (Hospira), an IV formulation of the NSAID diclofenac sodium, for use in adults. It can be administered alone for treatment of mild to moderate pain or in combination with opioid analgesics for moderate to severe pain. Dyloject is the first injectable formulation of diclofenac to become available in the US.
Med Lett Drugs Ther. 2015 Dec 21;57(1484):171-2 | Show Introduction Hide Introduction

Empagliflozin/Metformin (Synjardy) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Dec 21, 2015  (Issue 1484)
and metformin. It is the third SGLT2 inhibitor/metformin combination to be approved in the US.1 Empagliflozin ...
The FDA has approved Synjardy (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin (Jardiance) and metformin (Glucophage, and others), for treatment of patients with type 2 diabetes not adequately controlled on either of these drugs alone or already being treated with both empagliflozin and metformin. It is the third SGLT2 inhibitor/metformin combination to be approved in the US.
Med Lett Drugs Ther. 2015 Dec 21;57(1484):172-4 | Show Introduction Hide Introduction

In Brief: Oral Phenylephrine for Nasal Congestion

   
The Medical Letter on Drugs and Therapeutics • Dec 21, 2015  (Issue 1484)
mg were no more effective than placebo in reducing symptomatic nasal congestion.1 Other recent ...
In 2007, an FDA advisory committee asked that placebo-controlled, dose-ranging trials be conducted to establish the efficacy of the oral decongestant phenylephrine (Sudafed PE, and others), which is sold over the counter (OTC) as a single agent and in combination with other drugs for treatment of cold and allergy symptoms. Phenylephrine replaced pseudoephedrine (Sudafed, and others) in many OTC formulations when access to pseudoephedrine-containing products was restricted in an effort to reduce their use in the synthesis of methamphetamine.CLINICAL STUDIES — In a randomized, open-label,...
Med Lett Drugs Ther. 2015 Dec 21;57(1484):174 | Show Introduction Hide Introduction